Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ETRA · NASDAQ · Biological Products, (No Diagnostic Substances) · No 10-K yet
Electra Therapeutics (ETRA) · oqro.io/stocks/ETRA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$8.84−0.27 (−2.96%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
Yes. Insiders of Electra Therapeutics (ETRA) filed 32 open-market purchases in the last 90 days; the latest was filed on Nov 11, 2026.
Since 2026, Electra Therapeutics insiders reported 32 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
No open-market sale by an insider of Electra Therapeutics (ETRA) was filed with the SEC in the last 90 days.
No trade in Electra Therapeutics (ETRA) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−33.3% (−$4.41) from Sep 18, 2026 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $13.25 on Sep 18, 2026 to $8.84 on Nov 13, 2026 (−33.3%). Disclosed in this range: 32 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in South San Francisco, CA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
–
Short interest: 484K shares sold short, +18.2% vs the previous count, 1.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Electra Therapeutics: 2 insiders (all officers or directors) bought $1.5M on the open market (12 purchases combined) and 1 fund opened or increased a position in the latest available 13F filings. 2 of 3 tracked groups show buying activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Traded Nov 6 – Nov 10, 2026 · largest single transaction ~$311K
Nov 6, 2026~$311K · 40K sh @ $7.85
DetailsOfficial recordNov 10, 2026~$175K · 21K sh @ $8.45
DetailsOfficial recordTraded Nov 6 – Nov 10, 2026 · largest single transaction ~$311K
Nov 6, 2026~$311K · 40K sh @ $7.85
DetailsOfficial recordNov 10, 2026~$175K · 21K sh @ $8.45
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Fails to deliver: 506K shares (about $6.71M) were not delivered on time for settlement on Sep 21, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Insiders of Electra Therapeutics reported 32 open-market purchases and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $8.7M32×32 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Nov 13, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up free1 active phase 3 trial and 0 active phase 2 trials led by this company, mostly in secondary hemophagocytic lymphohistiocytosis (shlh). The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
On the public record for Electra Therapeutics over the 12 months to Nov 14, 2026: 1 clinical trial.